Bristol-Myers shares set for a meaningful run, says Credit Suisse Yesterday, Bristol-Myers stopped its Phase III CheckMate 066 study due to superior overall survival. Credit Suisse believes believes several other melanoma trials could stop early that 066 is positioned to be the first anti-PD1 agent approved ex-U.S. and that the FDA will likely accept it as well. The analyst believes Bristol-Myers shares are positioned for a meaningful run driven by immuno-oncology catalysts over the next 6-12 months and reiterates its Focus List Outperform rating and $59 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.